MAPK1 and polycystic ovary syndrome: In summary, this study preliminarily indicates via network pharmacology and proteomics that ZGP may ameliorate the hormonal disturbances of PCOS by suppressing the phosphorylation of JNK/ERK, key nodes within the MAPK pathway.